Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Washington, DC 20057-1465, USA.
J Cell Mol Med. 2010 Jun;14(6B):1468-75. doi: 10.1111/j.1582-4934.2009.00924.x. Epub 2009 Oct 3.
To determine the hypermethylation status of the promoter regions of tumour suppressor genes in breast tissues from healthy women and identify the determinants of these epigenetic changes. Questionnaires and breast tissues were collected from healthy women without a history of cancer and undergoing reduction mammoplasty (N= 141). Methylation for p16(INK4), BRCA1, ERalpha and RAR-beta promoter regions from breast tissues were determined by methylation specific PCR. Associations were examined with chi-square and Fisher's exact test as well as logistic regression. All statistical tests were two-sided. p16(INK4), BRCA1, ERalpha and RAR-beta hypermethylation were identified in 31%, 17%, 9% and 0% of the women, respectively. Women with BRCA1 hypermethylation had an eight-fold increase in the risk of ERalpha hypermethylation (P= 0.007). p16(INK4) hypermethylation was present in 28% of African-Americans, but 65% in European-Americans (P= 0.02). There was an increased likelihood of p16(INK4) or BRCA1 hypermethylation for women with family history of cancer (OR 2.3; 95%CI: 1.05-4.85 and OR 5.0; 95%CI: 1.55-15.81, respectively). ERalpha hypermethylation was associated with family history of breast cancer (OR 6.6; 95%CI: 1.58-27.71). After stratification by race, p16(INK4) in European-Americans and BRCA1 hypermethylation in African-Americans were associated with family history of cancer (OR 3.8; 95%CI: 1.21-12.03 and OR 6.5; 95%CI: 1.33-31.32, respectively). Gene promoter hypermethylation was commonly found in healthy breast tissues from women without cancer, indicating that these events are frequent and early lesions. Race and family history of cancer increase the likelihood of these early events.
为了确定健康女性乳房组织中肿瘤抑制基因启动子区域的超甲基化状态,并确定这些表观遗传变化的决定因素。我们从没有癌症病史且正在接受乳房缩小术的健康女性(N=141)中收集了问卷和乳房组织。通过甲基化特异性 PCR 确定了 p16(INK4)、BRCA1、ERalpha 和 RAR-beta 启动子区域的甲基化。采用卡方检验和 Fisher 确切检验以及逻辑回归分析进行关联检验。所有统计检验均为双侧检验。分别有 31%、17%、9%和 0%的女性存在 p16(INK4)、BRCA1、ERalpha 和 RAR-beta 超甲基化。BRCA1 超甲基化的女性发生 ERalpha 超甲基化的风险增加了 8 倍(P=0.007)。非洲裔美国人中有 28%存在 p16(INK4)超甲基化,而欧洲裔美国人中有 65%存在 p16(INK4)超甲基化(P=0.02)。有癌症家族史的女性发生 p16(INK4)或 BRCA1 超甲基化的可能性增加(OR 2.3;95%CI:1.05-4.85 和 OR 5.0;95%CI:1.55-15.81)。ERalpha 超甲基化与乳腺癌家族史相关(OR 6.6;95%CI:1.58-27.71)。按种族分层后,欧洲裔美国人的 p16(INK4)和非洲裔美国人的 BRCA1 超甲基化与癌症家族史相关(OR 3.8;95%CI:1.21-12.03 和 OR 6.5;95%CI:1.33-31.32)。在没有癌症的健康女性的乳房组织中普遍发现基因启动子超甲基化,表明这些事件是常见的早期病变。种族和癌症家族史增加了这些早期事件的可能性。